Oleg Markov
Overview
Explore the profile of Oleg Markov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
79
Followers
0
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Awad M, Senkova A, Zenkova M, Markov O
Scand J Immunol
. 2025 Jan;
101(2):e70001.
PMID: 39865924
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of immature myeloid cells playing a critical role in immune suppression. In vitro-generated MDSCs are a convenient tool to study the properties...
2.
Oshchepkova A, Chernikov I, Miroshnichenko S, Patutina O, Markov O, Savin I, et al.
Front Bioeng Biotechnol
. 2024 Nov;
12:1437817.
PMID: 39493304
Introduction: Small membrane particles called extracellular vesicles (EVs) transport biologically active cargo between cells, providing intercellular communication. The clinical application of EVs is limited due to the lack of scalable...
3.
Oshchepkova A, Markov O, Evtushenko E, Chernonosov A, Kiseleva E, Morozova K, et al.
Pharmaceutics
. 2021 Nov;
13(11).
PMID: 34834326
The main advantage of extracellular vesicles (EVs) as a drug carrier system is their low immunogenicity and internalization by mammalian cells. EVs are often considered a cell-specific delivery system, but...
4.
Ukrainskaya V, Rubtsov Y, Pershin D, Podoplelova N, Terekhov S, Yaroshevich I, et al.
Small
. 2021 Oct;
17(45):e2102643.
PMID: 34605165
Development of CAR-T therapy led to immediate success in the treatment of B cell leukemia. Manufacturing of therapy-competent functional CAR-T cells needs robust protocols for ex vivo/in vitro expansion of...
5.
Markov O, Oshchepkova A, Mironova N
Front Pharmacol
. 2019 Nov;
10:1152.
PMID: 31680949
Dendritic cell (DC)-based anti-tumor vaccines have great potential for the treatment of cancer. To date, a large number of clinical trials involving DC-based vaccines have been conducted with a view...